Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Temedica logo — Best for patients. Smart for healthcare.

Temedica

Best for patients. Smart for healthcare.

Founded 2016 Germany Germany 66 employees Series B Total: $42.00M

General Information

Company Name Temedica
Founded Year 2016
Location Germany Germany +1
Employees 66
Funding Stage Series B
Social

Get notified when Temedica moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Aug 20, 2026

Temedica has announced a new partnership with Lundbeck to jointly offer a personal migraine check for patients, providing them with an initial overview of their condition.

Event Participation Aug 18, 2026

Temedica is organizing a peer exchange event on September 30, 2026, at their Munich office, inviting experienced pharma decision-makers.

Get alerts when Temedica shows new signals

About Temedica

Temedica, headquartered in Germany, is a prominent player in the pharma technology sector since its inception in 2016. Positioned as the "commercialization partner you love to work with," Temedica delivers cutting-edge, AI-driven solutions and services tailored for the pharma industry.

The company specializes in leveraging real-world insights and configurable, AI-powered solutions to empower pharma companies, enhancing their brand performance through strategic planning and execution. With its deep medical and commercial expertise, Temedica addresses challenges in pharma's go-to-market strategies, translating them into measurable successes.

Recently, in a significant growth milestone, Temedica secured a €25.00M Series B investment on 01 November 2022 from MIG Capital. This funding underscores investor confidence in its innovative approach and its potential to drive substantial value in the pharma sector.

Taxonomy: AI-powered solutions, pharma industry solutions, real-world insights, patient journey data, personalized medicine, individualized medicine, Real-World Evidence, SaaS dashboard, health data analysis, digital healthcare, health insights, treatment adherence, biotech industry services, omnichannel engagement, medical expertise

Services & Products

Permea Insight Hub
Omnichannel Engagement Suite
Market Insights & Analysis
Competitive Benchmarking
Launch Excellence
Brand Strategy & Management
Stakeholder Engagement
Patient Journey Analysis

Target Customers

pharmaceutical companies medical teams marketing teams sales teams patient engagement teams business intelligence teams

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 1
Investor
01 Nov 2022
Series A •••••• 4
Investor
•••• •••• 		01 Jan 2020

Temedica Alternatives & Competitors

View All Alternatives
Temedica vs
Hyfe
Hyfe United States

AI-powered cough-tracking & insights. Precision medicine for respiratory health

Seed
44 employees
AI, Health Care
Compare Temedica vs Hyfe
Temedica vs
ZRx Outcomes Research Inc.
ZRx Outcomes Research Inc. Canada

If you need Real World Data analytics, look no further.

5 employees
Pharmaceutical
Compare Temedica vs ZRx Outcomes Research Inc.
Temedica vs
Aster Insights
Aster Insights United States

Accelerating oncology medical product discovery and development through our scientific and clinical...

Private Equity
78 employees
Biotechnology, Health Care
Compare Temedica vs Aster Insights
View all alternatives

FAQ About Temedica

Best for patients. Smart for healthcare.
Temedica was founded in 2016.
Temedica is headquartered in Germany.
Temedica has approximately 66 employees.
Temedica has completed 2 funding rounds, raising a total of $42.00M. The latest funding stage is Series B.
Temedica offers: Permea Insight Hub, Omnichannel Engagement Suite, Market Insights & Analysis, Competitive Benchmarking, Launch Excellence, Brand Strategy & Management, Stakeholder Engagement, Patient Journey Analysis, Real-World Evidence Generation, Medical Communication.
Top alternatives and competitors to Temedica include Hyfe, ZRx Outcomes Research Inc., Aster Insights, physIQ, Reuters Events Pharma USA (formerly eyeforpharma Philadelphia). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Temedica and Hyfe are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Temedica and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy